Eli Lilly achieves breakthrough with Imlunestrant in Phase 3 breast cancer trial

Eli Lilly and Company has announced encouraging results from its Phase 3 EMBER-3 study evaluating imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), for ... Read More